Sunday, March 01, 2026

 

Variety: Spice of life or risk factor for overeating?




Penn State
virtual reality buffet 

image: 

a diner fills their plate in the virtual reality buffet

view more 

Credit: Travis Masterson and John Long




UNIVERSITY PARK, Pa. — At Super Bowl parties, weddings, Independence Day cookouts and Thanksgiving dinners, people celebrate with large spreads of food. When faced with many options, extra food variety increases people’s selection of foods, especially calorie-rich foods, which may lead to overeating, according to a new study conducted by researchers in the Penn State Department of Nutritional Sciences. 

“This study examined what drives people to overconsume food at a buffet similar to dining halls, where millions of college students eat every day,” said John Long, first author of the study and postdoctoral scholar in food science and nutritional sciences. “If we identify the aspects of our modern food environment — excessive variety, slick packaging, processed foods and more — that increase how much people eat, we can redesign our environment to help us make healthier food choices.” 

Prior studies at Penn State and elsewhere indicated when people eat from a plate with many different foods, they will consume more calories. The current study, published in the journal Appetite, demonstrated that greater food variety affected how much food people served themselves before taking their first bite. The researchers found that the presence of a higher variety of foods in a buffet increased both the weight of food selected and the number of calories people put on their plates. 

How a VR buffet works 

The researchers recruited 50 people between the ages of 18 and 65 to visit their laboratory for three sessions, one week apart, all scheduled at either lunch or dinner. During those sessions, participants selected a meal they wanted to consume from a virtual-reality (VR) buffet. 

The buffet presented participants with a different number of food items at each visit — either nine, 18 or 27 choices. The buffet included a similar proportion of high-energy-dense foods — like cookies — and low-energy-dense foods — like vegetables — regardless of the number of food options available. Participants were instructed to abstain from exercise, food and caffeine for several hours prior to the visit to make sure they were hungry. 

Participants wore a VR headset and entered a VR buffet restaurant where they were able to select foods as they would at an actual buffet using videogame-style controllers in each hand. The system recorded the weight and calories of the selected meal along with the quantity of foods, including high-energy-density and low-energy-density foods.  

Prior research by Long and Travis Masterson, assistant professor of nutritional science at Penn State and senior author of the study, demonstrated that people at a VR buffet select similar food to what they would at a real buffet. Knowing that the buffets provide meaningful data, Masterson said using a VR buffet helps save money and time, leading to more efficient research.  

“It is costly and wasteful to make an entire buffet so that a single participant can use it at mealtime, especially if that participant needs to go through the buffet multiple times, like in this study,” Masterson said. “And when we need a different setup, it is much easier to change a setting in VR than it is to alter the amount of food on a buffet.” 

Variety affects eating behavior 

Participants who visited the buffet with nine food items selected just over 600 grams of food. People at the buffet with either 18 or 27 food items selected more than 900 grams of food. Although people took more food when variety increased, there appeared to be a general upper limit to the total weight of food people selected, according to Long, who earned his doctorate from Penn State in 2025.  

“External factors clearly influence what and how much people eat,” Long said. “But there seems to be a ceiling to the total weight of food selected for a meal, even as variety increases.” 

Despite the upper limit of food weight that people served themselves, the calories selected did not follow the same pattern. Participants who visited the buffet with nine food items selected an average of 850 calories of food. That rose to 1,320 calories — roughly 55% more — when 18 foods were offered, and to nearly 1,500 calories when 27 foods were available. That amounts to a 75% increase compared with what the same participants took from the nine-item buffet.  

“When presented with more options, people became more likely to choose higher calorie-dense foods,” Long said. “In the U.S., many people consume more calories than they need, and the wide variety of foods in our environment may nudge us to eat more than we otherwise would.  

Preventing overeating

The researchers surveyed participants about their personalities and other factors that could affect food selection. These surveys included a person’s tendency to seek out food variety, whether a person engaged in emotional eating, and their reluctance to try new foods.

Of the five major personality traits in this study — openness, extraversion, agreeableness, neuroticism and conscientiousness — only conscientiousness made a difference. People who scored higher in conscientiousness— a trait linked with self-discipline and goal-directed behavior — were less responsive to the greater variety of foods. When more options were available, they added fewer calories by limiting their selection of energy-dense foods compared to participants lower in conscientiousness. 

“We can all be a little more conscientious about our food choices and conscious of our environment,” Masterson said. “Behavior change starts with being aware of the things that influence us. If we are aware that variety might tempt us to eat more than is healthy, we may be able to make better decisions for our health.” 

Redesigning the eating environment

In the long run, Masterson and Long said they hope this research will go beyond promoting awareness and help us redesign the ways we encounter food in the world around us.

“Experts have been warning people for decades to watch what they eat, and the obesity epidemic has only increased,” Masterson said. “Clearly, our food environment is overriding our ability to limit our diets.”

Long agreed, and repeated that the eventual goal of this work is improving the food environment for everyone.

“By understanding the factors that drive our choices, we hope to be able to design eating environments that support health rather than overconsumption,” he said.

Other Penn State researchers who contributed to this study include Kathleen Keller, Helen A. Guthrie Chair and professor of nutritional sciences; and Barbara Rolls, distinguished professor of nutritional sciences also contributed to this research. Paige Cunningham, assistant professor of nutritional sciences at Cornell and former postdoctoral researcher at Penn State, also contributed to this research.  

 

Acoziborole Winthrop, developed by DNDi and Sanofi, receives European Medicines Agency positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness





Drugs for Neglected Diseases Initiative





The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion to Acoziborole Winthrop (acoziborole) as a single-dose oral treatment for both early- and advanced-stage gambiense sleeping sickness in adults as well as in adolescents 12 years and older weighing at least 40 kilograms.

A positive CHMP opinion through the EU-M4all procedure provides a strong endorsement that the medicine meets EU standards. This pathway, which engages WHO disease experts and regulators from endemic countries, is reserved for high-priority medicines addressing diseases with unmet medical needs. This decision will support regulatory approval of the treatment in the Democratic Republic of Congo (DRC) and lay the groundwork for a revision of the WHO’s sleeping sickness treatment guidelines. Such an update would ultimately broaden access to the medicine across other endemic countries in Central and West Africa.

Once approved in endemic countries, the medicine, co-developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, could provide a significant advance over current therapies. Existing treatments require either a 10-day course of oral medicine or a combination of injections and oral therapy for advanced cases.

In just 20 years, we have gone from complicated treatments including arsenic derivatives with serious side effects, to today, when a single-dose, one-day therapy could safely cure patients,’ said Dr Luis Pizarro, Executive Director at DNDi. ‘This progress is testament to the transformative power of collaborative science and will bring us closer to finally eliminating sleeping sickness, a disease that has killed millions on the African continent in the past century.

Transmitted by the bite of an infected tsetse fly, human African trypanosomiasis, commonly known as sleeping sickness, is almost always fatal without treatment. In the early stage of the disease, people experience headaches or fever. In the late stage, the parasite crosses the blood-brain barrier and invades the central nervous system, causing behavioural, cognitive, and neurological symptoms, including seizures, sleep disturbance, aggression, confusion, lethargy, convulsions, and, ultimately, death.

DNDi conducted a pivotal Phase II/III study in the DRC and Guinea in partnership with national sleeping sickness control programmes, while Sanofi carried out the regulatory approval process. The CHMP positive opinion is based on clinical and non-clinical data provided by the partners, with efficacy and safety supported by the Phase II/III study, published in The Lancet Infectious Diseases medical journal, which demonstrated success rates at 18 months of up to 96 per cent across both stages of the disease with a good safety profile.

The development of acoziborole and today’s positive scientific opinion is a victory for Africa-led science, made possible thanks to African doctors and researchers who conducted cutting-edge pharmaceutical research in some of the most remote and difficult-to-reach areas on the continent,’ said Dr Erick Miaka, Director of the DRC’s national sleeping sickness control programme.

In 1998, nearly 40,000 cases of gambiense sleeping sickness were reported, with an estimated 300,000 undiagnosed. At the time, the only available treatment for those with the late stage of the disease was an injectable arsenic derivative with serious side effects. More than two decades of investment in new therapeutic tools resulted in increasingly improved treatments, including nifurtimox-eflornithine combination therapy in 2009 and the first oral treatment, fexinidazole, in 2018. In 2024, fewer than 600 cases of the disease were reported.

For decades, Sanofi has maintained an unwavering commitment to the fight against sleeping sickness, standing alongside DNDi, the World Health Organization, and other partners in one of the most enduring and successful public-private health collaborations,’ said Audrey Duval, Executive Vice President, Corporate Affairs at Sanofi. ‘Together, we have helped drive cases to historic lows—achieving a remarkable 98% reduction since 2001—by putting patients first and investing in innovation where it is needed most. Acoziborole builds on this legacy and represents a decisive step forward in eliminating gambiense sleeping sickness by 2030.

Sanofi will donate Acoziborole Winthrop to the WHO through its philanthropic organization, Foundation S – The Sanofi Collective. The medicine will be available free of charge to patients.

Another study underway in the DRC and Guinea is investigating Acoziborole Winthrop for the treatment of children ages 1 to 14.

About the DNDi programme for the development of acoziborole

The DNDi programme for the development of acoziborole was supported by grants from the Federal Ministry of Research, Technology and Space (BMFTR) through KfW, Germany; the BBVA Foundation (through the ‘Frontiers of Knowledge Award in Development Cooperation’); Dutch Ministry of Foreign Affairs (DGIS), the Netherlands; European and Developing Countries Clinical Trials Partnership Association (EDCTP2 programme) supported by the European Union; Global Health EDCTP3 and its members; Gates Foundation; Médecins Sans Frontières International; Norwegian Agency for Development Cooperation (Norad), Norwegian Ministry of Foreign Affairs, as part of Norway’s in-kind contribution to EDCTP2; Swiss Agency for Development and Cooperation (SDC); Swiss State Secretariat for Education, Research and Innovation (SERI); Stavros Niarchos Foundation; Spanish Agency for International Development Cooperation (AECID); UK International Development; and other private foundations and individuals.

About DNDi’s sleeping sickness programme

Acoziborole Winthrop is the first oral single-dose new chemical entity to be issued from DNDi’s lead optimization programme for sleeping sickness. It started with an initial hit identified in the chemical library of Anacor Pharmaceuticals, which was acquired by Pfizer in 2016. The initial structure was then optimized with Scynexis and Pace University and was then selected as a candidate for development and Phase I safety studies conducted successfully in France, the UK, and Malaysia.

Acoziborole Winthrop is the latest innovation, the result of more than two decades of scientific collaboration involving DNDi, Sanofi, and partners. In 2009, they developed a combination of existing drugs known as NECT, which was extremely effective and had a good safety profile. A donation programme was set up by Sanofi and Bayer to provide NECT free of charge to endemic countries through the World Health Organization (WHO), radically improving treatment options for patients.

DNDi, Sanofi, and partners developed fexinidazole, which in 2018 became the first all-oral treatment available for gambiense sleeping sickness. This 10-day treatment is now available in all sleeping sickness-endemic countries.

Acoziborole Winthrop can be administered as a single oral dose, potentially without the need of systemic hospitalization or supervision of the treatment at home. This means it could become a major tool to facilitate efforts to finally eliminate sleeping sickness.

About DNDi

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit medical research organization that discovers, develops, and delivers safe, effective, and affordable treatments for neglected populations. DNDi is developing medicines for sleeping sickness, leishmaniasis, Chagas disease, river blindness, mycetoma, dengue, paediatric HIV, cryptococcal meningitis, and hepatitis C. Its research priorities include children’s health; gender equity and gender-responsive R&D; and diseases impacted by climate change. Since its creation in 2003, DNDi has collaborated with public and private partners worldwide to deliver new treatments for six deadly diseases, saving millions of lives. Acoziborole is the 14th treatment delivered by DNDi. dndi.org

About Sanofi

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

DNDi media relations

Frédéric Ojardias – Geneva | +41 79 431 62 16 | fojardias@dndi.org
Linet Atieno Otieno – Nairobi | +254 733 624 206 | latieno@dndi.org
Ilan Moss – New York| +1 646 266 5216 | imoss@dndi.org

Sanofi media relations

Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com
Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com 

Additional quotations from partners and supporters

UK Minister for Development, Jenny Chapman said:

Sleeping sickness is a neglected disease which affects some of the poorest communities in rural Africa. It invades the central nervous system and is almost always fatal without treatment. Not so long ago, the only treatment for sleeping sickness was a toxic injection with grim side-effects, so the development of a single-dose oral treatment is a historic milestone for combatting the disease. The UK’s partnership with the Drugs for Neglected Diseases Initiative has helped deliver this breakthrough, bringing the world one step closer to eliminating sleeping sickness by 2030. We will continue backing world-class scientists, because research like this saves lives around the world.

Director General, Africa CDC, H.E. Dr. Jean Kaseya said:

This breakthrough brings Africa closer to eliminating sleeping sickness and reflects the growing strength of African scientific leadership. The next step is to ensure innovation translates into sustainable access for the communities most at risk. Africa CDC supports efforts to explore producing treatments like acoziborole in Africa—advancing pharmaceutical manufacturing, strengthening supply resilience, and reinforcing Africa’s health security, consistent with Africa CDC’s drive to expand local production capacity across the continent.

African Union Commissioner for Health, Humanitarian Affairs and Social Development, H.E. Amb. Amma Adoma Twum-Amoah said:

Today marks a historic victory for health equity in Africa. We are turning what once required hospital beds into a simple cure, removing the last mile barriers to ending sleeping sickness for good. This milestone proves that when global solidarity meets African leadership, innovation does not remain in laboratories, it reaches villages, families and the very heart of our communities.

L’ambassadrice santé mondiale pour la France, Anne-Claire Amprou, a déclaré :

« La France félicite DNDi et Sanofi pour cette nouvelle étape franchie dans la lutte contre la maladie du sommeil. Fruit de l’innovation médicale, le développement de l’acoziborole, médicament révolutionnaire permettant de lutter contre cette maladie parasitaire, marque un moment décisif pour protéger les communautés et patients situés au cÅ“ur des régions endémiques de cette maladie. Mettre l’expertise scientifique française au service de la lutte contre les maladies vectorielles, notamment par la mise en Å“uvre de l’approche « Une seule Santé », est un axe prioritaire de la stratégie française en santé mondiale 2023 – 2027 et du One Health Summit qui se tiendra à Lyon, le 7 avril 2026. »

Executive Director, Global Health EDCTP3, Dr Michael Makanga said:

The development of acoziborole is a powerful exemplar of how sustained investment in locally-led clinical research creates high-impact solutions for the most vulnerable populations – here people at risk of sleeping sickness in all settings, even in the most remote communities. Building on the paediatric evidence from the EDCTP2-funded ACOZI-KIDS project and now the StrogHAT consortium supported by Global Health EDCTP3, evaluations are in full swing to turn a one-dose oral cure into a practical screen-and-treat tool that can interrupt transmission and bring us closer to eliminating gambiense human African trypanosomiasis by 2030.

L’ambassadeur de l’Union européenne en Guinée, Xavier Sticker, a salué cette innovation :

« La lutte contre la maladie du sommeil fait aujourd’hui un nouveau pas en avant grâce à un partenariat d’acteurs de l’Equipe Europe, incluant des organisations non gouvernementales et le secteur privé. Avec l’arrivée de l’acoziborole, il suffira de prendre une seule dose pour le traitement de cette maladie endémique. Ainsi, le diagnostic et le traitement pourront être administrés conjointement et facilement sur place.

En Guinée, la maladie du sommeil était un problème sanitaire majeur depuis longtemps. Grâce à une collaboration entre les services publics, la communauté scientifique, les chercheurs et les organisations de la société civile, cette maladie a pu être reconnue il y a un an par l’Organisation mondiale de la santé comme ne constituant plus un problème de santé publique. Grâce à cette innovation européenne qu’est l’acoziborole, une étape supplémentaire pourra être franchie : la prise en charge des cas résiduels sera facilitée et toute résurgence de la maladie sera contenue, avant que l’on parvienne à son éradication complète.

Cette solution européenne, validée aujourd’hui par l’EMA, est porteuse d’espoir pour la population en Guinée et au niveau mondial. L’Équipe Europe demeure un acteur fortement engagé dans le secteur de la santé en Guinée, à travers le renforcement d’un système de santé de qualité, au service de l’ensemble de la population. »

 

Cooling without gases: molecular design brings solid-state cooling closer to reality





Institut Laue-Langevin
Molecular structure and phase behaviour of neopentyl plastic crystals. 

image: 

Molecular structure and phase behaviour of neopentyl plastic crystals.

(a) Tetrahedral neopentyl molecules that differ only in the number of hydroxyl (–OH) groups. The –OH groups are shown in red (oxygen) and white (hydrogen).

(b) Simplified phase diagram showing different solid phases. α and β correspond to different ordered crystal phases, where molecules are fixed in position and orientation. γ corresponds to a disordered (plastic crystal) phase, where molecules can rotate more freely. The green hatched region indicates coexistence of ordered and disordered phases during the transition, and the red dot marks the composition studied in this work.

view more 

Credit: communications materials (2026)





Cooling technologies at a crossroads

Refrigeration is an essential part of modern life, from food preservation and medical storage to climate control and industrial processes. However, most of today’s systems still rely on vapour-compression cycles using refrigerant gases that contribute to global warming and face increasing regulatory constraints. This has triggered research into alternative solutions that are both efficient and sustainable.

One promising route is the use of solid materials that can absorb or release heat when pressure is applied or removed: these are known as barocaloric materials. For practical applications, these materials must:

  1. have nearly identical behaviour on heating and cooling (operate reversibly, with minimal thermal hysteresis); and
  2. be efficient under pressures relevant for real-world operation, typically of the order of 1 kbar.

Balancing these requirements without sacrificing their cooling capacity remains challenging.

Among barocaloric materials, plastic crystals  have attracted particular interest because they display a strong cooling response close to room temperature. This behaviour arises from a transition between disordered and ordered crystal phases. The associated entropy change reflects how much heat can be absorbed or released during this transition. In many cases, however, only a small fraction of this entropy change can be accessed reversibly under realistic operating conditions, limiting their use in practical cooling cycles.

 

Engineering molecular interactions to improve reversibility

Researchers from the University of Glasgow, the University of Cambridge,  Universitat Politècnica de Catalunya, Diamond Light Source and the ILL examined how the barocaloric behaviour of plastic crystals can be improved through compositional tuning. In their work, they investigated neopentyl glycol (NPG), a well-known barocaloric plastic crystal that exhibits a large caloric response at its order–disorder phase transition, but whose practical use is limited by strong thermal hysteresis.

To bring the transition temperature (T0 - the temperature around which the barocaloric effect is strongest) closer to room temperature, NPG was first combined with pentaglycerine (PG) to form a binary solid solution. An NPG:PG ratio of 60:40 yields a single-phase solid solution with a T0 ≈ 302 K (≈ 29 °C) which is about 10 degrees lower than that of pure NPG and 50 degrees lower than that of pure PG.

The key result of the study emerges with the introduction of a third molecular component. Adding only 2 mol % of pentaerythritol (PE), corresponding to an NPG:PG:PE ratio of 60:38:2, leads to a pronounced improvement in reversibility. At pressures around 1 kbar, the ternary material exhibits a reversible entropy change of 13.4 J kg⁻¹ K⁻¹, about seven times larger than that of pure NPG under similar conditions. Importantly, this reversible response extends over a temperature range of 18 K, representing an approximately twenty-fold increase in the usable operating window. When combined, these two effects enhance the reversible refrigeration capacity by more than a factor of seventy.

Crucially, this improvement is not achieved by weakening the cooling effect itself. The material still absorbs and releases a large amount of heat during the transition. Instead, the small amount of PE alters the molecular environment in a way that reduces the thermal hysteresis as the material is compressed and decompressed.

 

Neutrons reveal the microscopic origin of improved reversibility

To understand why a small compositional change leads to such a large improvement in barocaloric reversibility, it is necessary to go beyond thermodynamic and structural measurements and directly probe molecular dynamics. The team turned to quasielastic neutron scattering (QENS), which is ideally suited to this task. By measuring very small energy transfers, corresponding to molecular motions on picosecond to nanosecond timescales, QENS provides direct access to rotational and translational dynamics in hydrogen-rich molecular solids.

In this study, QENS measurements were performed on the IN16B spectrometer at the Institut Laue-Langevin (ILL). Using a measurement mode known as inelastic fixed-window scans, the instrument allows molecular dynamics to be followed at selected temperatures during heating and cooling. This makes it possible to directly correlate dynamic behaviour with the thermal hysteresis observed in calorimetry and with structural information from diffraction.

The neutron measurements show that adding a small amount of pentaerythritol modifies how molecular motion evolves with temperature. In the ternary NPG–PG–PE material, molecular reorientations develop more gradually across the phase transition, extending over a broader temperature range than in pure neopentyl glycol.

In contrast, pure NPG shows a more abrupt onset of motion and a clearer difference between heating and cooling. In the ternary material, this difference is reduced, indicating more similar behaviour in both directions of the transition. The team explains this effect with large hydrogen bonded structures that stabilize the ordered phase in pure NPG and NPG:PG, but are easily disrupted by adding small amounts of PE.

Taken together, the neutron results show that the enhanced reversibility of the barocaloric effect in the ternary material is rooted in a change in how molecular motion develops across the order–disorder phase transition. By revealing this microscopic origin of hysteresis reduction, neutron scattering provides a crucial link between molecular design and macroscopic cooling performance.

From molecular insight to sustainable cooling technologies

This study shows how subtle molecular engineering can address one of the central challenges in barocaloric materials: achieving large cooling effects under conditions that are compatible with practical use. By combining compositional tuning with a detailed investigation of molecular dynamics, the researchers demonstrate that cooling performance and reliability can be improved at the same time.

More broadly, this work illustrates how understanding materials at the molecular level can guide the development of efficient solid-state cooling technologies with lower environmental impact than conventional refrigerant-based systems. As the demand for sustainable cooling solutions continues to grow, such insights will be essential for turning promising physical effects into technologies with real societal impact.


Panoramic view inside IN16B's secondary spectrometer at the ILL 

Panoramic view inside IN16B's secondary spectrometer at the Institut Laue Langevin (ILL).

Credit

ILL (2026)